Residency · Residency · Radiation Oncology

Liver SBRT: Motion Management and Normal Tissue Considerations

Introduction

Stereotactic body radiation therapy (SBRT) has become an established treatment modality for liver tumors, including both primary hepatocellular carcinoma (HCC) and liver metastases, particularly in patients who are not candidates for surgery. Liver SBRT presents unique challenges such as managing respiratory motion, preserving sufficient functional liver volume, and avoiding excessive radiation to nearby dose-sensitive gastrointestinal structures. This lecture addresses strategies for motion management, appropriate dose-fractionation schemes, and critical normal tissue constraints to optimize treatment outcomes.

Indications

Hepatocellular Carcinoma

SBRT is indicated primarily for patients with Child-Pugh A liver function, although select patients with Child-Pugh B7 may be treated cautiously. It is used for tumors that are not amenable to surgical resection, transplantation, or ablation. Additionally, SBRT can serve as bridge therapy prior to liver transplantation or as salvage therapy following failed transarterial chemoembolization (TACE) or radiofrequency ablation. Typically, lesions smaller than 6 cm are treated, as larger tumors require more cautious dosing to minimize toxicity.

Liver Metastases

SBRT is appropriate for patients with oligometastatic disease, generally defined as having 1 to 5 liver metastases. Colorectal cancer metastases are the most extensively studied indication, but other histologies such as breast, lung, and neuroendocrine tumors are also treated. SBRT is reserved for unresectable or medically inoperable patients and for lesions that are not suitable for thermal ablation due to size or proximity to major vessels.

Contraindications

Patients with Child-Pugh C cirrhosis are generally excluded due to the high risk of liver failure. Insufficient remaining functional liver volume also precludes safe treatment. Tumors abutting or invading the stomach or duodenum represent a relative contraindication; in such cases, a fractionated approach may be considered to reduce toxicity. Diffuse hepatic disease without a focal treatable target is another contraindication.

Motion Management Strategies

Respiratory Motion Assessment

Four-dimensional computed tomography (4D-CT) simulation is mandatory to characterize tumor motion throughout the respiratory cycle. Liver tumors typically move 1 to 3 cm in the cranio-caudal direction during breathing. The internal target volume (ITV) approach involves encompassing the tumor in all respiratory phases to ensure coverage. The amplitude of tumor motion guides the choice of motion management strategy.

Abdominal Compression

An external compression device, such as an abdominal compression plate, restricts diaphragmatic excursion and reduces cranio-caudal tumor motion to less than 1 cm in most patients. This method is generally well tolerated with minimal discomfort. However, reproducibility between simulation and treatment must be verified to ensure consistent tumor positioning.

Breath-Hold Techniques

Breath-hold methods include the use of an active breathing coordinator (ABC), which enables the patient to hold their breath at a reproducible lung volume. Deep inspiration breath hold (DIBH) is another technique that displaces the liver inferiorly, away from the heart, and is reproducible. Voluntary breath hold, coached at end-expiration or end-inspiration, also reduces tumor motion. These techniques reduce the size of the ITV and allow for tighter planning target volume (PTV) margins. They require cooperative patients with adequate respiratory function.

Respiratory Gating

In respiratory gating, the treatment beam is activated only during a specific phase of the respiratory cycle, typically at end-expiration, which is the most reproducible phase. This approach reduces the effective treatment volume but prolongs treatment time. Real-time tumor tracking systems, such as CyberKnife Synchrony or MR-LINAC, enable continuous adaptation during treatment delivery.

Fiducial-Based Tracking

Gold fiducial markers are implanted percutaneously near the tumor to facilitate real-time tracking. Position monitoring is performed using kV imaging or electromagnetic tracking systems like Calypso. This enables real-time tumor tracking and gated delivery. To minimize the risk of fiducial migration, implantation is performed at least one week before simulation.

Dose and Fractionation

Liver Metastases

For liver metastases located at a safe distance from gastrointestinal structures, doses of 50 to 60 Gy delivered in 3 to 5 fractions are typical. When lesions are near the stomach or duodenum, a dose of 45 to 50 Gy in 5 fractions is used. For lesions proximal to bowel, more conservative doses of 30 to 40 Gy in 5 fractions are applied in a risk-adapted manner. One-year local control rates range from 80 to 95% with ablative doses.

Hepatocellular Carcinoma

Dose selection for HCC depends on liver function and tumor size. Patients with Child-Pugh A liver function typically receive 40 to 50 Gy in 5 fractions or 30 to 50 Gy in 3 to 5 fractions. Those with Child-Pugh B7 receive lower total doses, usually 25 to 40 Gy in 5 fractions. The mean liver dose constraint is a key factor driving prescription, and individualized dosing is recommended. The NRG/RTOG 1112 trial is a randomized study comparing sorafenib with or without SBRT in HCC.

Dose-Response Relationship

Local control improves with a biologically effective dose (BED10) greater than 100 Gy. For metastases, the goal is to achieve BED10 above 100 Gy when normal tissue constraints permit. For HCC, a BED10 between 80 and 100 Gy is targeted, with lower doses used in patients with cirrhosis to reduce toxicity.

Normal Tissue Constraints

Liver Parenchyma

A critical threshold for liver tolerance is that at least 700 cc of uninvolved liver must receive less than 15 Gy in 3 fractions or less than 17 Gy in 5 fractions. The mean liver dose, excluding the gross tumor volume (GTV), should be kept below 13 to 15 Gy in 3 fractions and below 15 to 18 Gy in 5 fractions. For HCC patients with cirrhosis, more conservative constraints apply, with over 800 cc of liver spared below 15 Gy. The risk of radiation-induced liver disease (RILD) increases with higher mean liver doses and baseline liver dysfunction.

Gastrointestinal Structures

For the stomach and duodenum, the maximum dose (Dmax) should be less than 30 Gy in 5 fractions and less than 22.5 to 24 Gy in 3 fractions. The dose to 5 cc (D5cc) of these structures should remain below 18 Gy in 3 fractions. The small bowel should receive a Dmax of less than 30 Gy in 5 fractions. Gastrointestinal toxicity is the dose-limiting factor for central or medial liver lesions.

Other Organs at Risk

The spinal cord maximum dose should be limited to 18 to 21 Gy in 3 fractions and 25 to 30 Gy in 5 fractions. For the kidneys, the volume receiving 15 Gy (V15) should be less than 35% for each kidney. The heart should receive a maximum dose below 30 Gy in 5 fractions. Dose to the chest wall and ribs should be minimized to reduce the risk of pain and fractures.

Treatment Planning

Imaging

Treatment planning requires 4D-CT with intravenous contrast or MRI fusion for superior soft tissue delineation. MRI simulation is increasingly used due to its superior tumor visualization. MR-LINAC platforms enable real-time MRI-guided adaptive SBRT, allowing for online plan adaptation during treatment.

Target Delineation

The gross tumor volume (GTV) is defined as the visible tumor on contrast-enhanced imaging. The internal target volume (ITV) encompasses the GTV motion envelope derived from 4D-CT. The planning target volume (PTV) is created by adding a margin of 3 to 5 mm to the ITV, depending on the motion management strategy employed. Breath hold or tracking techniques allow for smaller PTV margins compared to free-breathing ITV approaches.

Plan Optimization

Volumetric modulated arc therapy (VMAT) or multiple non-coplanar beams are used for plan optimization. Heterogeneous dosing within the GTV is acceptable, with hot spots reaching up to 120 to 140% of the prescription dose. Priority is given to respecting organs-at-risk (OAR) constraints, and dose de-escalation is performed if constraints cannot be met. The prescription isodose line typically ranges from 60 to 80%.

Radiation-Induced Liver Disease (RILD)

Classic RILD

Classic RILD presents with anicteric hepatomegaly, ascites, and elevated alkaline phosphatase, occurring between 2 weeks and 4 months after radiation therapy. Pathologically, it corresponds to veno-occlusive disease. This complication is rare with SBRT when dose constraints are respected.

Non-Classic RILD

Non-classic RILD manifests as elevated transaminases greater than five times baseline or a decline in liver function indicated by worsening Child-Pugh score. It is more common in HCC patients with baseline cirrhosis and occurs in 5 to 15% of such patients even with appropriate dosing. The pre-treatment Child-Pugh score is the strongest predictor of non-classic RILD.

Key Clinical Pearls

Four-dimensional CT simulation is mandatory for liver SBRT, and motion management strategies such as abdominal compression, breath hold, or respiratory gating reduce the treated volume and improve the therapeutic ratio. It is essential to spare at least 700 cc of uninvolved liver below 15 Gy in 3 fractions to prevent radiation-induced liver disease. Proximity to gastrointestinal structures is the dose-limiting factor for central liver lesions, necessitating dose de-escalation or fractionation when tumors abut the stomach or duodenum. For liver metastases, achieving a BED10 greater than 100 Gy maximizes local control, whereas for HCC, the dose should be adjusted based on liver function. MR-LINAC platforms provide real-time adaptive SBRT with superior soft tissue visualization and online plan adaptation, enhancing treatment precision.

References

1. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847-2854.
2. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631-1639.
3. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572-1578.
4. Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94-S100.

Read this lecture as Markdown